Vergelijking
CagriSema vs. Pramlintid
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
geen gegevens
151126-32-8
Molecuulmassa
geen gegevens
3949.4 g/mol
Halfwaardetijd
geen gegevens
geen gegevens
Sequentie
geen gegevens
geen gegevens
Werkingsmechanisme
CagriSema
CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.
Pramlintid
Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
1
0
waarvan bij mensen
1
0
Geregistreerde effecten
2
2
Openstaande tegenstrijdigheden
0
1
Gedocumenteerde bijwerkingen
1
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between CagriSema and Pramlintid?
- CagriSema is classified as "Metabool", while Pramlintid is classified as "Metabool". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CagriSema or Pramlintid?
- The highest available evidence level is "Humane RCT" for CagriSema and "Humane RCT" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CagriSema and Pramlintid in Germany and the United States?
- Duitsland: CagriSema — Niet goedgekeurd, Pramlintid — Niet goedgekeurd. Verenigde Staten: CagriSema — Niet goedgekeurd, Pramlintid — Op recept. These are factual summaries with source and review date on the individual pages.